


Data Sheet

Product Name:	Naftopidil
Cat. No.:	CS-2477
CAS No.:	57149-07-2
Molecular Formula:	C ₂₄ H ₂₈ N ₂ O ₃
Molecular Weight:	392.49
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Solubility:	H ₂ O : < 0.1 mg/mL (insoluble); DMSO : 33.33 mg/mL (84.92 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

Naftopidil (Flivas), a selective α_1 -adrenergic receptor antagonist or alpha blocker, is an antihypertensive drug. Target: α_1 -Adrenergic Receptor Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2 ± 7.9 to 11.7 ± 5.8 in the M group and from 19.4 ± 6.4 to 12.3 ± 6.8 in the E group ($p < 0.0001$), QOL score from 4.9 ± 0.8 to 3.2 ± 1.4 in the M group and from 5.0 ± 0.8 to 3.6 ± 1.3 in the E group ($p < 0.0001$), and OAB symptom score from 7.8 ± 2.6 to 5.0 ± 2.5 in the M group ($p < 0.0001$) and from 8.6 ± 2.9 to 5.8 ± 3.3 in the E group ($p < 0.0001$). Naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration [1]. The selectivity of Naftopidil for prostatic pressure was the most potent among the test compounds. In addition, using cloned human α_1 -adrenoceptor subtypes, Naftopidil was selective for the α_{1D} -adrenoceptor with approximately 3- and 17-fold higher affinity than for the α_{1A} - and α_{1B} -adrenoceptor subtypes, respectively. The selectivity of Naftopidil for prostatic pressure may be attributable to its high binding affinity for α_{1A} - and α_{1D} -adrenoceptor subtypes [2].

References:

- [1]. Sakai, H., et al., [Efficacy of Naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication]. Hinyokika Kiyo, 2011. 57(1): p. 7-13.
- [2]. Takei, R., et al., Naftopidil, a novel α_1 -adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α_1 -adrenoceptors. Jpn J Pharmacol, 1999. 79(4): p. 447-54.

CAIndexNames:

1-Piperazineethanol, 4-(2-methoxyphenyl)- α -[(1-naphthalenyloxy)methyl]-

SMILES:

OC(CN1CCN(C(C=CC=C2)=C2OC)CC1)COC3=CC=CC4=CC=CC=C34

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA